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1. Introduction 
Crohn’s disease (CD) is a chronic disorder of the gastrointestinal tract, which was 
characterized by a relapsing–remitting course with trans-mural inflammation of potentially 
any section of the digestive tract, leading to various intestinal and extra-intestinal 
manifestations. Although the etiology is currently unknown, inflammation, immunity, 
genetic and environmental factors have been suggested to predispose to CD.  
The precise etiology of CD is not yet elucidated but the mucosal system is the central 
effector of intestinal inflammation and injury (Fig 1). The dysregulated mucosal immunity 
of the bowel is contributed by varied factors among which cytokines play a central role in 
modulating inflammation. Others are gut associated lymphoid tissues (GALT), pathogen 
recognition receptors (PRRS), professional antigen presenting cells (APCs), epithelial cells of 
gut and resident microflora, etc.  
1.1 Cytokines 
There are two types of cytokines: anti-inflammatory cytokines (IL-10, IL-11, etc) and 
proinflammatory cytokines (IL-1, IL-2, IFNǄ, TNFǂ, IL-12, IL-18, etc). The anti-inflammatory 
cytokines have some beneficial effects in CD. IL-10 is produced by Th2 cells and suppresses 
the production of IL-2 and IFNǄ by Th1 cells. Evidences showed that IL-10 and IL-11 might 
be therapeutic agents in CD. IL-10 knockout mice develop severe transmural and 
granulomatous inflammation of the small and large bowel, reminiscent of CD, and the 
inflammation can be prevented by the administration of IL-10. IL-11 is derived from 
mesenchymal cells. Studies showed that IL-11 could attenuate the inflammatory response 
and enhance the integrity of the intestinal mucosa. Among the proinflammatory cytokines, 
TNFǂ is the most important and widely investigated factor. TNFǂ is secreted into intestinal 
mucosa by macrophages and monocytes and is bound to T lymphocytes and monocytes. Its 
biological activity is mediated by cell surface TNFǂ receptors binding to either membrane-
bound or soluble TNFǂ. TNFǂ may increase adhesion molecules, allowing for increased cell 
infiltration and enhanced metalloproteinase and collagenase production, which help form 
ulcers and fistulas. It can also mediate recruitment of leukocytes from blood vessels into 
intestinal mucosa through circulating cells interacting with adhesion molecules on the 
vascular endothelium. TNFǂ also activates increases the production of IFNǄ by mucosal T 
cells independently of IL-12 and IL-18. It activates CD44 in T cells and enhances 
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intraepithelial lymphocyte proliferation and migration. Multiple antibodies to TNFǂ have 
proven effective in both induction and maintenance of remission for CD. TNFǂ appears to 
be a determinant in granuloma formation, and, together with IL-6, IL-1 may contribute to 
the constitutional symptoms of IBD and lead to the generation of acute-phase proteins. 
 
 
Fig. 1. Intestinal mucosal (immune) homeostasis in healthy state (Dharmani P, 2008) 
Mucosal homeostasis is maintained by professional APCs (DC) that differentiate pathogens 
from commensals through TLRs and leads to balanced differentiation of naive T cells into 
effector T cells (Th1, Th2 and Th17) against pathogens and Treg and Th3 cells to control the 
inflammation in absence of pathogens. Epithelial cells lining, tight junction proteins and 
mucus layer remains intact separating luminal antigen from immune cells. 
1.2 PPRs 
The recognition, processing and presentation of the luminal antigen is carried out by both 
dedicated APCs such as dendritic cells (DCs) and macrophages, and non-professional APCs 
such as epithelial cells. Two PRRs namely Toll-like receptor (TLR) and Nucleotide binding 
Oligomerization Domans (NOD) proteins are involved in luminal antigen recognition. TLRs 
are membrane bound receptors while NOD proteins are expressed in the cytosols of APCs. 
PPRs recognize molecules shared by pathogens but distinguishable from commensal 
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microbes. Such unique microbial components are collectively referred to as pathogen-
associated molecular patterns (PAMP), which include CpG regions of methylated DNA, 
viral specific ssRNA and dsRNA, peptidoglycans, muramyl dipeptide (MDP) and lipo-
polysaccharides. Both animal and in vitro studies have shown and exaggerated TLR 
expression (especially TLR4), that leads to an incorrect immune response (Th1 or Th17 
mediated) against resident microflora. NOD2/CARD15 gene is famous as it is the first 
predisposing gene of CD. Mutations of the NOD2/CARD15 gene have conclusively 
associated with CD. Both gain and loss of expression of NOD2 gene contributes in 
disturbing mucosal homeostasis. Loss of NOD2 expression cause change in TLR signaling 
pathway and thus leads to an increase in Th1 cytokine and defensins. In contrast, gain of 
expression eventually leads to more Th1 response against the MDP component of microbes. 
1.3 T cell polarisation 
T helper cells have been classified as either Th1 or Th2 on the basis of function and 
according to their ability to elaborate specific cytokines. Th1 cells orchestrate cell-mediated 
immune responses and are characterized by their ability to secrete IL-2, IFNǄ and TNFǃ. 
IFNǄ activates APCs and macrophages to produce IL-12, thereby driving Th1 cells to 
produce even larger amounts of Th1 cytokines. In contrast, Th2 cells mediate humoral 
responses and secrete IL-4, IL-5, IL-6, IL-10 and IL-13. These subsets regulate each other 
reciprocally through key cytokines. IFNǄ, produced by Th1 cells, suppresses the 
development of Th2, whereas IL-4, IL-10 and IL-13, secreted by Th2 cells, inhibit Th1 
responses (Fig 2).CD is thought to be associated with Th1 cell cytokines and inhibition of 
Th1 responses could represent a significant goal in the treatment of CD. Intestinal Th1 
activation and cytokine release are associated with the generation of activated matrix 
metalloproteinases (MMPs), which are essential mediators of tissue destruction.  
 
 
Fig. 2. T-helper (Th)-1 and Th2-mediated cytokine profiles and immune response. IL = 
interleukin; IFN = interferon ( Ardizzone S, 2005). 
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2. Common categories of biological therapy 
Traditionally, the therapeutic goals in CD include チinduction of a rapid response, ヂ 
maintenance of glucocorticoid-free remission, ッ minimization of complications and 
surgery, ツ prevention of disease-related mortality, ヅ improvement in patients’ quality of 
life, テ minimization of the adverse effects of treatment, and デ the so-called ‘deep 
remission’ (i.e. simultaneous clinical, biological and endoscopic remission). Both mucosal 
healing and deep remission need to be evaluated for their prediction of long-term outcome 
and benefit/risk ratio if treatment escalation becomes necessary. 
Existing CD therapies are an amalgamation of pharmacological agents including 5-
aminosalicylate compounds, corticosteroids, and immunosuppressors (azathioprines, 6-
mercaptopurine, methotrexate, tacrolimus and cyclosporine). Novel biological therapies 
have been developed in recent years based on better understanding of specific 
immunopathological processes in intestinal inflammation. There are several categories of 
biologic therapies that are relevant to CD: 1) antibody-based therapy (monoclonal 
antibodies, receptor fusion proteins, and soluble receptor antagonists), 2) recombinant 
cytokines, 3) nucleic acid-based therapies, 4) hormones and growth factors, 5) cell and gene 
therapy. At present, the biotechnology therapies that are being used in clinical practice or 
investigated for the treatment of CD are predominantly proteins, usually delivered 
intravenously or subcutaneously. The types of therapeutic proteins in used include 
recombinant human proteins with immunoregulatory effects, monoclonal antibodies 
(chimeric, humanized and fully human) and fusions proteins. Here we chose to focus on 
therapies that have been used in clinical trials in CD, some of which have been already or 
may be in the near future approved for commercial daily use (table 1). 
 
Therapy Target Origin Efficacy Side effects 
Inhibition of pro-inflammatory cytokines 
Infliximab 
TNFǂ 
Mouse/human 
chimeric mab 
Safe, being used in 
treatment 
Risk of malignancy and infection, 
infusion site reactions 
Adalimumab 
Human IgG1 
mab 
Safe, being used in 
treatment 
Risk of malignancy and infection, 
infusion site reactions 
CDP571 Fusion protein Still in clinical trial
Risk of malignancy and infection, 
infusion site reactions 
Onercept 
Human soluble 
TNFǂ p55 
receptor 
Still in clinical trial Local reaction 
Etanercept Fusion protein 
Safe but 
ineffective in 
treatment CD 
Itching, pain, swelling and redness 
at the site of injection 
CDP-870 
PEGylated anti-
TNFǂ ab Under clinical trial No reported major side effects 
IL-1 R ab IL-1 R 
Recombinant IL-
1 R antagonist 
No double 
placebo control 
tried yet 
Not fully established 
Anti-IL-6 R 
ab 
IL-6 R Human mab Under clinical trial Not fully established 
Anti-IL-12 
p40 ab 
IL-12 Human mab Safe and effective Possible reactivation of asthma 
Fontolizumab IFNǄ Human mab Under phase 
IIclinical trial 
Not fully established 
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Supplementation of regulatory cytokines 
Tenovil IL-10 
Recombinant 
cytokine 
Failed to show 
efficacy in phase II 
clinical trial 
Reaction at injection site 
Turbo 
probiotics 
IL-10 
Lactobacillus 
lactis 
Effective in clinical 
study 
Not fully established 
IL-11 IL-11 
Recombinant 
cytokine 
No efficacy in 
phase II clinical 
trials 
Not fully established 
Inhibition of proliferation of T cells 
Visilizumab CD3 Human ab Under clinical trial Not fully established 
Daclizumab 
ǂchain of IL-
2R 
Human mab 
Failed to show 
efficacy in phase II 
clinical trial 
Hypersensitivity 
Basiliximab 
ǂ chain of 
IL-2R 
Human mab Under clinical trail
Mild dizziness, nausea, rashes on 
skin 
Blocking molecule involved in leukocyte adhesion 
Natalizumab Integrin-ǂ4 Human mab Approved by FDA
Sometimes causes fatal brain 
infection (progressive multifocal 
leukoencephalopathy) 
MLN-02 ǂ4ǃ7integrin Human mab Under clinical trial Infusion reaction 
Supplementation of growth factor 
somatropin  
Recombinant 
human growth 
hormone
Under clinical trial Not intense severe adverse reactions 
Nucleic acid based therapies
alicaforsen ICAM-1 
Antisense 
phosphorothioat
e oligonucleotide
Under phase III 
clinical trials 
Not fully established 
Recompositon of intestinal microflora
Probiotics 
Reconstituti
on of 
commensal 
microbes
Combination of 
different bacteria
Under clinical 
trials 
 
helminthes 
Inhibition of 
excessive 
immune 
response
Helminthes 
Under clinical 
trials 
Not fully established 
Reconstitution of the immune system
Hematopoietic 
stem cell 
transplantation 
Replacement
of defected 
hematolymp
hatic cells
Infusion of the 
healthy 
hematopoietic 
cells
Under clinical trial
Toxic effects of high dose 
chemotherapy and post HCT 
infections 
R: receptor; ab: antibody; mab: monoclonal antibody; ICAM-1: intracellular adhesion molecule-1 
Table 1. Biological Therapies targeting different factors (Dharmani P, 2008) 
3. Evaluations of biological treatment 
3.1 Anti-TNFα therapies 
Anti-TNFǂ mAb is the first agent that was approved for patients with persisting signs and 
symptoms of disease refractory impact in achieving new therapeutic goals. Till now, several 
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anti-TNFǂ reagents have been developed and used to inhibit TNFǂ in patients with CD, 
including the mouse/human chimeric monoclonal antibody (infliximab), the humanized 
monoclonal antibody CDP571 and D2E7 (adalimumab), the human soluble TNFǂ p55 
receptor (onercept), the p75 soluble TNFǂ receptor fusion protein (etanercept), and the 
polyethylene glycol (PEG)ylated anti-TNFǂ antibody fragment CDP-870 (certolizumab 
pegol). Peyrin B L and his colleagues performed a meta-analysis including 21 trials to 
evaluate safety and efficacy of tumor necrosis factor (TNF) antagonists for Crohn's disease 
(Peyrin-Biroulet L, 2008). They concluded that infliximab, adalimumab, and certolizumab 
are effective in luminal Crohn's disease. Efficacy of anti-TNF agents other than infliximab in 
treating fistulizing Crohn's disease requires additional investigations. Longer duration of 
following-up and larger number of patients are required to better assess the safety profile of 
TNF antagonists in CD. We also conducted a meta-analysis about anti-TNFǂ reagents 
treating CD. As a result, Fifteen RCTs articles with high quality were selected. Compared 
with placebo, anti-TNF-ǂ agents achieved significantly higher rates of clinical response 
(44.9% vs. 30.0%, RR=1.39, 95% CI: 1.16~1.67, P=0.0004) and clinical remission (29.3% vs. 
18.7%, RR=1.63, 95% CI: 1.26~2.09, P=0.0001). We concluded that Anti-TNF-ǂ agents are 
superior to placebo in the treatment of CD and have similar risks of adverse events and 
serious adverse events. Long-term trials with large samples are needed for the assessment of 
its safety and tolerance. Table 2 lists the administrations of some of these agents. 
3.1.1 Infliximab 
Infliximab is the only biologic agent approved in the China, US and Europe for the 
treatment of patients with moderate to severe CD unresponsive to conventional therapy or a 
full and adequate course of corticosteroids and immunosuppressive therapy, and for 
patients with actively draining fistulas. 
The first randomized placebo-controlled trial of infliximab focused on response rates 4 
weeks after a single-blind infusion (Targan SR, 1997). All patients presented moderate to 
severely active disease despite other treatments or had previously been unresponsive to 
treatment with immunomodulators. A single infusion yielded a decrease in the CDAI of ≥70 
points 4 weeks after infusion in 65% of the patients treated with infliximab, compared with a 
17% response in the placebo group. The highest response rate was observed in patients 
receiving infliximab 5mg/kg (81%), with lower response rates in those treated with 10 or 20 
mg/kg (50% and 64%, respectively). 
Rutgeerts et al conducted a study to find out whether repeated infusions of infliximab could 
maintain the response (Rutgeerts P, 1999). Seventy-three patients were randomized to 
receive infliximab or placebo 10 mg/kg every 8 weeks for 36 weeks and were followed up 
until week 48. At week 44, 52.9% patients received infliximab achieved maintenance of 
remission, compared with 20% of placebo-treated patients. Quality of life was consistently 
better (using a inflammatory bowel disease questionnaire) and serum concentrations were 
maintained at remission levels. 
The results were confirmed in the recent multicenter, randomized, placebo-controled, 
double-blind phase III clinical trial: the ACCENT I (A Crohn’s disease Clinical trial 
Evaluating infliximab in a New long-term Treatment regimen) study (Hanaeur SB, 2002). 
Five hundred and seventy three patients with active CD received infliximab 5mg/kg at 
week 0 and were assessed of response at week 2. The responders were then randomized into 
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3 groups. Group I received placebo at week 2 and 6 and then every 8 weeks until week 46. 
Group II received 5mg/kg infliximab at the same time points. Group III received 5mg/kg 
infliximab at week 2 and 6, but followed by 10mg/kg every 8 weeks until week 46. The 
endpoints were the proportion of patients who responded at week 2 and were in remission 
(CDAI<150) at week 30, and the time to loss of response up to week 54 in patients who 
responded. At week 2, 335 patients (58%) responded to infliximab. At week 30, 23 of 110 
(21%) patients in group I were in remission, compared with 44 of 113 (39%) in group II 
(P=0.003) and 50 of 112 (45%) in group III (P=0.0002). The study suggested that patients that 
were repeatedly administrated with infliximab every 8 weeks are more likely acquiring 
sustained clinical remission than those with single infusion. The safety was consistent with 
those in other clinical trials and serious infections were similar across the three groups. 
 
 Infliximab Adalimumab Certolizumab pegol 
Dosage 5 mg kg-1 40 mg 400 mg 
Route of 
administration 
i.v. s.c. s.c. 
Dosing intervals 8 weeks 2 weeks (e.o.w) 4 weeks 
Induction 
5 mg kg-1 weeks 0, 
2, 6 
168/80 mg (FDA) 
or 80/40 mg 
(EMA) 
400 mg weeks 0, 2, 4 
Dose escalation 
10 mg kg-1 or every 
4-6 weeks 
40 mg e.w. 400 mg e. o. w. 
i.v., intra venous; s.c., subcutaneous; e.w., every week; e.o.w., every other week; EMA, European 
Medicines Agency; FDA, Food and Drug Administration 
Table 2. Administrationof biologicalagents in inflammatory bowel disease (Nielsen, 2011) 
A study was conducted early in 1999 by Present DH, et al to investigate whether infliximab 
had the efficacy in healing enterocutaneous fistulas. In their study, 94 adult CD patients 
with fistulas were randomly assigned to receive placebo, 5mg/kg inflximab or 10mg/kg 
inflximab at weeks 0, 2 and 6. As a result, 55% patients assigned to receive 5mg/kg 
infliximab and 38% patients assigned to receive 10mg/kg infliximab had closure of all 
fistulas, as compared with 13% of the patients assigned to placebo. Adverse events were 
similar for the 5mg/kg infliximab group and the placebo group, but there was a trend 
toward more adverse events in the 10mg/kg group. 
The multicenter, randomized, placebo-controlled ACCENT II trial further confirmed the 
efficacy of infliximab as maintenance therapy for fistulas in CD (Sands BE, 2002). After 14-
week lead-in period, 195 of 282 (69%) patients responded. The responders were then 
randomized to receive either 5mg/kg infliximab or placebo every 8 weeks. Forty-eight 
percent of the infliximab group maintained fistula response at week 30 compared with 27% 
of the placebo group. At week 54, 36% of the infliximab group had a complete absence of 
draining fistulas compared with 19% of the placebo group.  
Infliximab is also efficacy for patients who are intolerant of, resistant to or dependent on 
steroids. On study showed that of the first 100 patients administered infliximab, 29 of 40 (73%) 
were able to completely withdraw from steroids (Ricart E, 2001). At study entry in the 
ACCENT I, more than half of the patients were taking corticosteroids; one third of the patients 
receiving maintenance infliximab discontinued steroids and maintained clinical benefit. 
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There is also evidences that infliximab likely has a role in treating some extraintestinal 
manifestations, such as ankylosing spondylitism peripheral arthritis, pyoderma 
gangrenosum and erythema nodosum. CD patients are at increased risk of low bone mineral 
density (BMD), with reports of prevalence of osteopenia and osteoporosis as high as 50% 
and 10%, respectively. Infliximab may improve BMD in CD patients. A prospective study 
was conducted by Abreu et al to evaluate the effect of infliximab on surrogate markers of 
bone turnover in 38 CD patients. The data obtained demonstrated that bone synthesis 
markers were increased in the infliximab-treated patients (Abreu MT, 2006). Longer-term 
studies are needed to clarify the effect of infliximab on BMD. 
Although efficacy of infliximab for the treatment of CD has clearly been demonstrated, 
serious side effects have been reported. In particular, these include acute infusion reactions, 
delayed hypersensitivity reactions, infections including reactivation of tuberculosis (TB), 
autoantibody formation, and a Lupus-like syndrome. Acute infusion reactions are adverse 
events that occur during infusion or within 2 hours after completion of the infusion. 
According to the manufacturer’s drug insert, 22% of patients administered infliximab 
occurred compared with 9% of patients administered placebo (Lichtenstein GR, 2011). 
Delayed-hypersensitivity reactions can occur several days after infusion. Symptoms include 
severe pruritus, headaches, hand, facial or lip swelling, myalgias, rash, sore throat, and 
dysphagia. In the ACCENT B study, the frequency of delayed hypersensitivity reaction was 
2%. Infections have been observed with pathogens, including viral, bacterial, fungal, and 
protozoal organisms. The majority of infections involved the respiratory and urinary tracts. 
Reactivation of latent TB after infusion with infliximab has occurred, mandating screening 
of patients for TB prior to infusion. A purified protein derivative (PPD) should be 
administered to all patients being considered for treatment with infliximab, with the results 
interpreted according to the risk atrata adapted from the American Thoracic Society (ATS), 
patients with a positive PPD should undergo a chest radiograph. Lymphoma has been 
reported in association with all 3 approved TNFǂ antagonists. A meta-analysis performed 
by Siegel et al suggested that the risk of lymphoma was increased in patients receiving 
infliximab for CD.  
Since infliximab contains exogenous proteins, it can prompt the formation of antibodies-to-
infliximab (ATIs) and thus may lead to the infusion reaction or loss of response. In ACCENT 
I trial, 64/442 (14.5%) developed antibodies. Patients administered a single dose of 
infliximab had higher incidence of ATI formation than those administered scheduled 
maintenance regiments of 5 or 10 mg/kg (28% vs 9% and 6%, respectively). The clinical 
response rates were similar in the patients regardless of their ATI status. The infusion 
reactions were more common in the ATI-positive patients compared with the ATI-negative 
group (16% vs 8%). The majority of the infusion reactions were mild to moderate.  
3.1.2 Adalimumab 
Adalimumab (first named D2E7) is a subcutaneously administered, recombinant, fully 
human, IgG1 monoclonal antibody that binds with high affinity and specificity to human 
TNFǂ, thus modulating its biologic functions by blocking the interaction with p55 and p75 
cell surface TNF receptors. It is available in a number of countries, including the US and EU 
countries.  
In CD, adalimumab has received both FDA and EMEA approval with the following 
indications: 1) for reducing the signs and symptoms and inducing and maintaining clinical 
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remission in adults with moderately to severely active CD who have had an inadequate 
response to conventional therapy, and 2) for reducing the signs and symptoms and inducing 
clinical remission in these patients if they have also lost response or are intolerant to IFX. 
Therefore, adalimumab is the second biologic therapy approved for the treatment of 
patients with moderately to severely active CD. Adalimumab is administered by 
subcutaneous injection, as commercially available prefilled pen (HUMIRA Pen) containing 
0.8 mL (40 mg) of drug. 
The recommended adalimumab induction dose regimen for adult patients with moderate-
severe CD is usually 80 mg at week 0 followed by 40 mg at week 2. In case there is a need 
for a more rapid response to therapy, the regimen with 160 mg at week 0 (dose can be 
administered as 4 injections in one day or as 2 injections per day for 2 consecutive days) and 
80 mg at week 2 can be used with the awareness that the risk for adverse events is higher 
during induction. After induction treatment, the recommended dose is 40 mg every other 
week via subcutaneous injection as maintenance treatment. For induction treatment, 
adalimumab should be given in combination with corticosteroids. Adalimumab can be 
given as monotherapy in case of intolerance to corticosteroids or when continued treatment 
with corticosteroids is inappropriate (Cassinotti A, 2008). 
In a phase III, placebo-controlled, dose-ranging induction trial named CLASSIC I (CLinical 
Assessment of adalimumab Safety and efficacy Studied as Induction therapy in Crohn’s 
disease), 299 patients with moderate to severe CD, naive to anti-TNF therapy were 
randomized to 4 groups. Patients in group I received adalimumab 40mg at week 0 and 20mg 
at week 2; patients in group II received adalimumab 80mg at week 0 and 40mg at week 2; 
patients in group III received adalimumab 160mg at week 0 and 80mg at week 2; patients in 
group IV received placebo at the same points. All the patients were followed through week 
4. A response was defined as a CDAI score reduction of ≥70 points (70-point response) or of 
≥100 points (100-point response) from week 0, while remission was defined as a CDAI score 
<150. At week 4, patients in group II and group III showed a significantly greater remission 
rate (24% and 36%) than patients in group IV (12%) (P=0.004 among the 3 groups). There 
was a linear dose response across the 3 adalimumab treatment groups at week 4 for the 
endpoints of remission and 100-point response, with only the highest dose group 
demonstrating statistical significance in the pairwise comparisons with placebo: 36% vs 12% 
for remission (p = 0.001) and 50% vs 25% (p = 0.002) for the 100-point response; the 70-point 
response was also significantly higher in the adalimumab recipients than placebo, both for 
the 160/80 mg dosage (59% vs 37%; p = 0.007) and for the 80/40 mg group (59% vs 37%; p = 
0.01). The reduction of CDAI from baseline was evident as early as week 1. Only 11% 
(32/299) of the randomized patients had draining enterocutaneous or perianal fistulas at 
baseline and were unevenly distributed across the treatment groups. The rates of fistula 
improvement and remission for the ADA-treated patients and those receiving placebo were 
not significantly different, but the number of these patients precluded a powered analysis 
(Hanauer SB, 2006).  
A total of 276 patients who completed the 4-week CLASSIC-I trial entered a long-term 
extension study named CLASSIC-II (Sandborn WJ, 2007). This was a randomized, placebo-
controlled, maintenance follow-up trial, demonstrating that adalimumab 40 mg every other 
week or weekly was superior to placebo in maintaining remission for 1 year in patients with 
moderate to severe CD naive to anti-TNF agents who achieved remission with adalimumab 
induction therapy. 
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Eligible patients (belonging to the pool of CLASSIC-I enrolled patients) were treated with 
adalimumab 40 mg at week 0 (corresponding to week 4 of CLASSIC-I) and week 2. Those in 
remission at both week 0 and week 4 (n = 55) were randomized to receive adalimumab 40 
mg every other week (n = 19), adalimumab 40 mg weekly (n = 18), or placebo (n = 18), 
through 56 weeks. 
At week 56, remission was maintained in 79%, 83%, and 44% of patients in the respective 
groups (primary endpoint), with a statistically significant difference between each 
adalimumab group and placebo (p< 0.05). The 100-point response at week 56 was also better 
in adalimumab recipients (79% vs 89% vs 56%, respectively), as was the 70-point response 
rates (79% vs 89% vs 72%), although differences between groups were not statistically 
significant. 
3.1.3 CDP571 
CDP571 was a humanised monoclonal antibody to human TNF-ǂ. It was constructed by 
linking the complementarity determining regions (CDR) of a murine antihuman TNF 
monoclonal antibody to a human IgG4 antibody. A total number of 396 patients with 
moderate to severe CD were included in a randomized, double blind and placebo controlled 
trial in 2004. The patients were received intravenous 10mg/kg CDP571 or placebo every 8 
weeks to week 24 and were followed up to week 28. Clinical response was defined as a 
decrease in the CDAI to ≥ 100 points or remission (CDAI score ≤ 150 points) at week 28. 
Initial clinical response occurred in 90/263 (34.2%) CDP571 patients and 28/32 (21.2%) 
placebo patients (P=0.011). At week 28, 80/263 (30.4%) CDP571 patients and 31/132 (23.5%) 
placebo patients achieved clinical response (P=0.102). Adverse events were similar in both 
groups. A post hoc analysis of a subgroup of patients with CRP concentrations ≥ 10mg/L 
demonstrated significantly increased response rates for CDP571 10mg/kg at both week 2 
and 28 (Sandborn WJ, 2004). Two controlled trials failed to demonstrate a steroid-sparing 
benefit of CDP571 in patients with steroid-dependent CD. Further clinical development of 
CDP571 for the treatment of CD has been discontinued. 
3.1.4 Certolizumab pegol 
Certolizumab pegol (CDP870) is a humanized TNFǂ Fab monoclonal antibody fragment 
linked to polyethylene glycol that is administered subcutaneously. A phase D, randomized, 
double-blind, multicenter study that assessed the efficacy and tolerability of certolizumab in 
patients with moderate to severe CD showed a modest improvement in response rates, as 
compared with placebo but no significant improvement in remission rates (Sandborn WJ, 
2007). In addition, patients who had a response to induction therapy with certolizumab 
were more likely to have maintained response and remission at 26 weeks with continued 
treatment compared with a switch to placebo. 
3.2 Other novel biological therapies 
3.2.1 Natalizumab 
Natalizumab is a recombinant humanized monoclonal antibody IgG4, with a molecular 
weight of 149 kDa. It contains 95% human peptide sequences and only 5% mouse sequences 
in the complementary determining regions. It inhibits both ǂ4ǃ7-integrin/MAdCAM-1 
interaction and ǂ4ǃ1/VCAM-1 binding. 
ENACT-1 (Efficacy of Natalizumab as Active Crohn’s Therapy) is a randomized double-
blind, placebo-controlled Phase III trial (Sandborn WJ, 2005), in which 905 patients were 
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randomly assigned in a 4:1 ratio to receive an intravenous infusion of 300mg natalizumab or 
placebo at week 0, 4 and 8. The patients were then followed until week 12. The primary end 
point was the proportion of patients who had a clinical response (ΔCDAI score ≥70 points). 
No difference in the response remission (CDAI < 150) rates was seen between the 
natalizumab group and the placebo group (P=0.051 and P=0.12, respectively). A significant 
difference of CRP was present in the subgroup of 660 patients who had a baseline CRP level 
more than 2.87 mg/l compared with the placebo group. 
The patients who responded in the ENACT-1 trial were randomly reassigned in a 1:1 ration 
to receive either natalizumab 300mg intravenously every 4 weeks or placebo and were 
followed up to 36 weeks (ENACT-2) (Sandborn WJ, 2004). At week 36, 61% of natalizumab 
patients had a sustained response compared with 28% in the placebo group (P<0.001). The 
remission rates was also significantly higher in the natalizumab group (44%) than in the 
placebo group (26%) at week 36 (P=0.003). Forty five percent of patients in the natalizumab 
group were no longer taking corticosteroids and remained in remission at week 36 
compared with 22% of patients in the placebo group (P=0.003).  
Natalizumab should not be given with immunomodulators (e.g.6-mercaptopurine, 
azathioprine, cyclosporine or methotrexate) or inhibitors of TNF-a. Corticosteroids should 
be tapered.  
Natalizumab is not approved in Europe for the treatment of CD. It is available in the USA 
under a special restricted distribution program called CD-TOUCH (Tysabri® outreach 
unified commitment for health). Under this program, prescribers, pharmacies, infusion 
centers and patients are made aware of risks of opportunistic infections, including PML. 
Patients are evaluated 3 months after the first infusion, 6 months after the first infusion and 
every 6 months thereafter. Any serious opportunistic or atypical infections are reported 
(Bickston SJ, 2010). 
3.2.2 Fontolizumab 
Fontolizumab is a humanized IgG1 antibody with high binding affinity and specificity for 
IFNǄ By inhibiting the binding of IFNǄ to its cellular receptor, fontolizumab prevents 
downstream physiologic effects, such as expression of major histocompatibility complex 
class II molecules. 
In a Phase C, randomized, double-blind, placebo-controlled study, 201 patients with CDAI 
scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 
4.0 mg/kg fotolizumab or placebo, and then were received 0.1 or 1.0 mg/kg fontolizumab 
or placebo every 4 weeks. The primary endpoint of efficacy evaluations was the proportion 
of patients who achieved a clinical response (defined as a decrease in the CDAI of ≥100 
points from baseline levels without an accompanying increase in dose of concomitant 
medications for CD) by day 29. Secondary endpoints were clinical response rates on days 43, 
57, 85, 113, and at the 3-month follow-up visit. The response rates were similar in all 
treatment groups (31%–38%) at day 29. At subsequent timepoints a significantly greater 
proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous 
fontolizumab group had clinical response and significantly greater improvement in the 
CDAI score compared with patients who received placebo. The CRP levels were 
significantly improved in the fontolizumab groups. The overall frequency of adverse events 
was similar in all groups (58%–75%) (Reinisch W, 2010). Further clinical studies with 
fontolizumab for the induction and maintenance of remission in patients with CD are 
anticipated. 
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3.2.3 Anti-IL-12 P40 antibody  
IL-12 is a heterodimeric molecule composed of IL-12 p40 and IL-12 p35 subunits. The p40 
subunit is also a component of IL-23, in which p40 forms a heterodimer with a p19 subunit. 
IL12/23 is a key cytokine in the Th1/Th17 development and is abundantly produced in the 
gut of CD patients. IL-12 p40 is, therefore, a pivotal target for the treatment of CD.  
A double-blind, placebo controlled randomized study of a humanized IgG1 monoclonal 
antibody against IL-12 p40 (ABT-874) was performed in 79 patients with active CD (Mannon 
PJ, 2004). The patients were randomized to receive seven weekly injections of 1 or 3 mg/kg 
anti-IL-12 or placebo subcutaneously either with or without 4 wk intervals between the first 
two injections. The patients who received 3 mg/kg anti-IL-12 for 7 wk showed a 
significantly greater clinical response rate than the patients treated with a placebo (75% vs 
25%). The production Th1 proinflammatory cytokines from patient’s colonic lamina propria 
mononuclear cells dramatically decreased after the anti IL-12 therapy. The most frequent 
adverse event was a local reaction at the injection site, which was observed with a greater 
rate in the anti IL-12 treated group than in the placebo-treated group. No serious side effects 
were observed during the anti-12 therapy. Anti IL-12 therapy is therefore considered to be a 
safe and effective treatment for active CD. 
4. Conclusion 
There are multiple biological therapies based on different targets in addition to those we 
introduced above. More clinical studies for the efficacy and safety should be conducted. 
Overall, the biological treatments differ from conventional CD therapy in several aspects: 
They are usually peptides or proteins; are administered parenterally; target specific 
molecules, cells, or processes; and their manufacture is more sophisticated and more 
expensive than the conventional drugs. The development of biological therapies is based on 
better understanding of mucosal intestinal processes in homeostasis and uncontrolled 
inflammation and is possible due to great biotechnological progress such as genetic 
engineering and development of novel vehicles. 
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